Blog

PharmaDrug Inc. Closes Acquisition of Securedose Synthetics

Nov 7 • 6 min read

PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLD) (“PharmaDrug” or the “Company“), is pleased to announce that it has closed the previously announced acquisition (see press release dated October 27, 2023) of Securedose Synthetics Inc. (“SecureDose“). PharmaDrug acquired all of the issued and outstanding shares of SecureDose by way of a three-cornered amalgamation between Pharmadrug, SecureDose…

Optimi Health Welcomes Dr. Preston A. Chase as New Chief Science Officer

Nov 7 • 4 min read

Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading Canadian psychedelics drug research and formulation company, is delighted to announce the appointment of Dr. Preston A. Chase as the Company’s Chief Science Officer (“CSO”). Dr. Chase is a distinguished Research & Development (“R&D”) chemist and seasoned business professional with an impressive academic and…

Revive Therapeutics Enters into Worldwide Exclusive Agreement with Lawson Health Research Institute to Develop and Commercialize a Novel Long COVID Rapid Test

Nov 6 • 4 min read

Potential world-first patented biomarker for long COVID Evaluating diagnostic companion with Bucillamine for long COVID Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, newly-formed subsidiary, Revive Diagnostics Inc., today announced that it…

Sunstone Therapies Announces Start of First Study of Multiple Doses of Psilocybin in Treatment of Depression in Patients with Cancer

Nov 6 • 4 min read

Sunstone Therapies Announces Start of First Study of Multiple Doses of Psilocybin in Treatment of Depression in Patients with Cancer Phase 2 study to examine safety and efficacy of up to two doses of psilocybin in cancer patients with major depressive disorder Sunstone Therapies, a leader in the delivery of psychedelic-assisted therapy in the medical…

DEA Announces Major Increase to 2023 Production Quotas for Psilocybin, THC and Ibogaine

Nov 6 • 2 min read

The U.S. Drug Enforcement Administration (DEA) is proposing a “dramatic increase” in this year’s production quotas for psychedelics ibogaine and psilocybin as well as marijuana compound delta-9 THC to “support research and clinical trials.” According to the proposal, the DEA would like to almost double its THC, psilocybin and psilocin production compared to its origin…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441442443444445446447448449450451452453454455456457458459460461462463464465466467468469470471472473474475476477478479480481482483484485486487488489490491492493494495496497498499500501502503504505506507508509510511512513514515516517518519520521522523524525526527528529530531532533534535536537538539540541542543544545546